In this whitepaper, Alithea Genomics demonstrates the performance of MERCURIUS™ 1536 DRUG-seq, an ultra-high-throughput, RNA-extraction-free 3′ mRNA-seq technology designed to…

Learn how 1536-well whole-transcriptome profiling, combined with Arctoris’ automated Ulysses® platform, can support reproducible, high-throughput compound profiling and perturbation dataset…

Drug-induced liver injury (DILI) remains a leading cause of drug attrition and post-market withdrawal, underscoring the need for more predictive…

Translating neuroscience discoveries into effective therapies remains challenging: in 2024, only around 7% of drug trials resulted in approved treatments,…

Scalable drug discovery demands phenotypic data that is both mechanistically rich and compatible with high-throughput, AI/ML-driven analysis, yet conventional RNA-seq…

What if AI could design a brand-new protein, from scratch, to tackle heart disease? That’s no longer science fiction. In…

Integrating mechanistic enzymology with precision experimentation techniques and streamlined data simulation capabilities brings new levels of detailed understanding to the…

Kinetic analysis plays a central role in drug discovery by characterising the temporal aspects of drug–target interactions. These studies provide…

The integration of machine learning (ML) into small-molecule drug discovery has long been heralded as the game-changer that would bring…

Foundation Models and the Power of Proprietary Experimental Data In recent years, foundation models have revolutionised fields from natural language…

Molecular glues are small molecules that can bind to two or more proteins, facilitating their interaction and potentially leading to…